Mezavant Xl (Mesalazine)

Mesalazine acts locally in the colon by inhibiting cyclooxygenase and lipoxygenase enzymes, which decreases the production of prostaglandins and leukotrienes. It also scavenges free radicals, providing a targeted anti‑inflammatory effect that reduces mucosal irritation and promotes healing.

The dosage of Mezavant XL is individualized by the prescribing clinician based on disease severity, patient weight, and response to therapy. The prescriber determines the appropriate strength and dosing schedule, which may be adjusted during the course of treatment.

Safety data for mesalazine during pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so clinicians must weigh potential benefits against possible risks. Breastfeeding mothers should discuss continuation with their healthcare provider.

To place an order, submit an enquiry on the Mezavant XL product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mezavant XL is an extended‑release formulation that delivers mesalazine throughout the colon, often allowing once‑daily dosing. Compared with immediate‑release tablets or sulfasalazine, it may improve adherence and provide more consistent mucosal exposure, though efficacy and safety remain comparable when used as directed.

Store Mezavant XL tablets at ambient temperature, preferably below 25 °C, in the original blister pack to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in bathrooms or near heat sources.

Mezavant XL is taken orally with a full glass of water. The tablet should be swallowed whole and not chewed, crushed, or split, to preserve the extended‑release coating that ensures gradual drug release in the colon.

Serious adverse events include myocarditis, severe allergic reactions such as anaphylaxis, blood dyscrasias (e.g., neutropenia), significant liver enzyme elevations, pancreatitis, and toxic colitis. Patients should seek immediate medical attention if they experience chest pain, rash, fever, jaundice, or severe abdominal pain.

Mezavant XL is contraindicated in individuals with known hypersensitivity to mesalazine or any component of the tablet. It should also be avoided in patients with severe renal impairment, active severe liver disease, or those who have experienced a serious reaction to other aminosalicylates.